Raj Ganesan

Company: Amgen Inc.

Job title: Executive Director, Oncology

Seminars:

Rational Combinations to Enhance Efficacy of Bispecific T Cell Engagers (BiTEs) in Solid Tumors 11:40 am

• Recent progress with development of bispecific T-cell engager (BiTE) molecules in solid tumors • Strategies to improve response rate and durability • Preclinical data for the DLL3-targeted BiTE molecule (IMDELLTRA™ / tarlatamab) in combination with standard of care and Immune check point inhibitors, and translation to the clinicRead more

day: Day One